Status:
UNKNOWN
Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma
Lead Sponsor:
Singapore National Eye Centre
Collaborating Sponsors:
National University Hospital, Singapore
Conditions:
Glaucoma
Eligibility:
All Genders
21+ years
Phase:
PHASE3
Brief Summary
Glaucoma is the leading cause of irreversible blindness worldwide. With ageing of the population, glaucoma morbidity will rise, causing increased health care costs and economic burden for a condition ...
Detailed Description
AIMS AND OBJECTIVES The primary aim of the study is to determine whether argon laser peripheral iridoplasty (ALPI) is an effective treatment in terms of intraocular pressure (IOP) control for cases o...
Eligibility Criteria
Inclusion
- Persistent narrow angle in the presence of a patent laser peripheral iridotomy. A narrow angle is defined as an angle width of 0-10º in 2 or more quadrants of either eye or where the pigmented trabecular meshwork is not visible in for 2 or more quadrants on gonioscopic examination
- Intraocular pressure \> 21mmHg on or off topical medication at least four weeks following laser iridotomy
- Intra ocular pressure \> 21 mm Hg after wash out regimen as described below for patients who are already on one medication and Iridotomy has been done at least 4 weeks ago.
- Informed Consent
- Age more than 21 years
Exclusion
- Age less than 21 years
- Secondary causes of angle closure like subluxed lens, uveitis, trauma and neovascular glaucoma
- Presence of advanced sight-threatening glaucoma defined as vertical cup-disc ratio \> 0.9
- Presence of significant synechial angle closure with \> 6 clock hours of peripheral anterior synechiae (defined as abnormal adhesions of the iris to the angle that are at least half a clock hour in width and be at least to the anterior trabecular meshwork or higher on indentation gonioscopy)
- Cataract that is deemed significant enough to require surgery during the course of the trial or that makes field testing or optic disc imaging not technically possible- visual acuity less than 20/40 due to any type of cataract.
- Corneal endothelial cell count less than 1000 cells/mm2
- Corneal abnormalities or infection
- Previous intraocular surgery
- Use of contact lens
- Chronic use of topical or systemic steroids
- Participation in another therapeutic drug study within the last 30 days
- Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, respiratory disease, or cancer and life expectancy less than one year.
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00980473
Start Date
September 1 2007
Last Update
June 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore National Eye Centre
Singapore, Singapore, 168751